Some preliminary evidence based on in vitro experiments and genetic analysis suggested that SGLT2 inhibitors have a preventative effect on prostate cancer occurrences, providing rationale for this TTE. In this study, we found that patients with prostate cancer receiving SGLT2 inhibitors experienced statistically significant longer time to treatment failure of hormone therapy than those who did not use SGLT2 inhibitors. This evidence concerns the gene SLC5A2 and prostate carcinoma.